No. Auvelity is not an antipsychotic. It is a combination of dextromethorphan and bupropion that was originally approved as an antidepressant. In April 2026, the U.S. Food and Drug Administration expanded its approval to include agitation associated with dementia due to Alzheimer’s disease, making it the first FDA-approved non-antipsychotic treatment for that condition. For example, a person with Alzheimer’s who repeatedly paces, shouts, or strikes caregivers may now be considered for Auvelity even when psychosis is not driving the behavior.
That distinction matters because Auvelity has a different drug classification, mechanism, and risk profile from antipsychotics such as Rexulti, also known as brexpiprazole. It does not treat the underlying causes of Alzheimer’s disease, restore lost memory, or slow cognitive decline. Its Alzheimer’s-related indication is specifically for ongoing agitation, and the prescribing information states that it should not be used only as needed during individual outbursts. Agitation can include excessive motor activity, verbal aggression, physical aggression, and severe restlessness. Before prescribing medication, clinicians generally look for correctable triggers such as pain, constipation, infection, medication effects, hunger, overstimulation, or an unfamiliar caregiver. A sudden episode of yelling accompanied by painful urination, for instance, calls for a medical assessment rather than an immediate assumption that Alzheimer’s agitation has worsened.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Is Auvelity an Antipsychotic or a New Alzheimer’s Agitation Option?
- How Auvelity Treats Agitation Associated With Alzheimer’s Dementia
- Auvelity Compared With Rexulti and Other Antipsychotics
- What Caregivers Should Check Before Starting Auvelity
- Side Effects, Interactions, and Common Safety Problems
- Dosing Auvelity for Alzheimer’s Agitation
- Monitoring Behavior After Auvelity Is Started
- Frequently Asked Questions
Is Auvelity an Antipsychotic or a New Alzheimer’s Agitation Option?
auvelity is a new Alzheimer’s agitation option, but it is not an antipsychotic. Dextromethorphan acts as an NMDA receptor antagonist and sigma-1 receptor agonist. Bupropion affects central nervous system signaling and inhibits the CYP2D6 enzyme, which slows the breakdown of dextromethorphan and increases its exposure in the body. The combination is pharmacologically different from antipsychotics, which primarily influence dopamine and serotonin receptors. The FDA initially approved Auvelity for major depressive disorder in adults.
On April 30, 2026, it was also approved for agitation associated with dementia due to Alzheimer’s disease in adults after randomized studies found benefits on measures of agitated behavior and relapse. The expanded indication does not mean that Alzheimer’s agitation is simply depression or that the medicine works by sedating everyone who takes it. The FDA describes Auvelity as the first approved non-antipsychotic drug for this condition. A practical comparison is Rexulti. Rexulti is an atypical antipsychotic and was the first medication specifically approved for agitation associated with Alzheimer’s dementia. Auvelity provides a non-antipsychotic alternative, but “non-antipsychotic” should not be mistaken for “risk-free” or “appropriate for every person with dementia.”.
How Auvelity Treats Agitation Associated With Alzheimer’s Dementia
Agitation is more than ordinary frustration or an occasional disagreement. Clinicians consider the frequency, severity, pattern, and consequences of behaviors such as pacing, repetitive movements, screaming, threatening language, resisting essential care, or hitting. In Auvelity’s clinical program, caregiver observations were assessed with the Cohen-Mansfield Agitation Inventory, a structured tool that records how often particular behaviors occur. One randomized study compared Auvelity with placebo over five weeks. Another enrolled people who had achieved a sustained response and examined whether continuing treatment delayed relapse compared with switching to placebo.
These designs support an effect on persistent agitation, but they do not establish that every form of distress in dementia will respond. A person who becomes upset only during a rushed bath may benefit more from changing the time, room temperature, caregiver approach, or bathing method. The limitation is especially important when behavior changes abruptly. Delirium caused by infection, dehydration, medication toxicity, low oxygen, urinary retention, or another acute illness may resemble severe agitation. Treating the behavior without investigating the cause can delay urgent care. new confusion, fever, a fall, weakness, reduced alertness, or a sudden inability to walk warrants prompt medical evaluation.
Auvelity Compared With Rexulti and Other Antipsychotics
Rexulti is brexpiprazole, an atypical antipsychotic. The FDA approved it for agitation associated with dementia due to Alzheimer’s disease in 2023. Like other antipsychotics, its labeling carries a boxed warning that older adults with dementia-related psychosis treated with antipsychotic drugs have an increased risk of death. Antipsychotics can also cause problems such as sedation, movement symptoms, metabolic changes, low blood pressure, and falls, although the exact risks vary by drug and patient. Auvelity does not carry the antipsychotic class warning because it is not part of that class.
Instead, it has its own safety concerns, including seizure risk, elevated blood pressure, dizziness, serotonin syndrome, activation of mania or hypomania, and other neuropsychiatric reactions. Its boxed warning concerns increased suicidal thoughts and behaviors in adolescents and young adults taking antidepressants; Auvelity is not approved for pediatric use. Dizziness deserves particular attention in dementia care because even a brief loss of balance can lead to a hip fracture or head injury. The choice is therefore not simply “dangerous antipsychotic versus safe non-antipsychotic.” Consider an older adult with a history of seizures and another with severe metabolic disease and medication-induced movement symptoms. Auvelity may be unsuitable for the first person, while an antipsychotic may create additional concerns for the second. The prescribing decision depends on medical history, current drugs, previous treatment response, fall risk, and the nature of the agitation.
What Caregivers Should Check Before Starting Auvelity
A useful first step is to bring the prescriber a complete medication list, including over-the-counter cough medicines, sleep aids, supplements, antidepressants, and drugs used only occasionally. Dextromethorphan appears in many cough and cold products, while bupropion is sold under several prescriptions for depression or smoking cessation. Accidentally combining duplicate ingredients can increase adverse effects. The clinician should check blood pressure and ask about seizures, eating disorders, bipolar disorder, liver or kidney problems, alcohol use, and recent changes involving sedatives or antiseizure medicines. Auvelity is contraindicated in people with a seizure disorder and in those with a current or previous diagnosis of anorexia nervosa or bulimia.
It should also not be used during certain periods involving monoamine oxidase inhibitors, and abrupt withdrawal from alcohol, benzodiazepines, barbiturates, or antiseizure drugs can make its use unsafe. Medication should be paired with a practical care plan. Compared with increasing a drug dose, reducing evening noise, treating arthritis pain, providing a familiar routine, and simplifying personal care carry fewer medication-related risks. A caregiver might track when pacing starts, what happened immediately beforehand, sleep during the previous night, bowel movements, food and fluid intake, and what helped. That record gives the clinician more useful information than a general report that the person was “agitated all week.”.
Side Effects, Interactions, and Common Safety Problems
In studies supporting the Alzheimer’s agitation indication, dizziness and indigestion were among the most common adverse reactions. The prescribing information also warns about seizures, increased blood pressure, angle-closure glaucoma, psychosis or other neuropsychiatric reactions, low sodium, and serotonin syndrome. A person who develops marked unsteadiness, fainting, a seizure, severe confusion, unusual muscle rigidity, fever, or rapidly worsening behavior needs prompt medical attention. Interactions can be clinically significant. Combining Auvelity with certain serotonergic medicines, including some antidepressants, can increase the risk of serotonin syndrome.
Bupropion inhibits CYP2D6, an enzyme involved in processing many medications, so it can change exposure to other drugs. Strong CYP2D6 inhibitors may require a lower Auvelity dosing limit, while strong CYP2B6 inducers should generally be avoided. The medicine can also affect digoxin levels and produce a false-positive urine screening result for amphetamines. Auvelity tablets must be swallowed whole rather than crushed, divided, or chewed. This can be a limitation for a person with swallowing difficulty or someone who routinely receives crushed medicines in applesauce. Caregivers should not alter the tablet without speaking with the prescriber or pharmacist, because doing so can disrupt the extended-release formulation.
Dosing Auvelity for Alzheimer’s Agitation
For agitation associated with Alzheimer’s dementia, the labeled regimen begins with a lower-strength tablet once each morning. It is increased gradually based on tolerability, first to twice-daily dosing and then, when appropriate, to the higher strength twice daily. Doses taken twice daily must be separated by at least eight hours.
Kidney function, CYP2D6 metabolism, interacting medicines, and side effects can require a lower maximum dose. Auvelity is not an as-needed rescue medicine. If a resident becomes combative during one dressing change, a caregiver should not give an extra tablet to control that episode. The prescribed schedule should be followed, and missed or delayed doses should be discussed with a pharmacist rather than doubled.
Monitoring Behavior After Auvelity Is Started
Monitoring should focus on observable changes rather than vague impressions. A care team might record the number of hitting episodes, minutes spent pacing, nights with repeated awakenings, attempts to leave the home, and occasions when essential care could not be completed. The same record should note dizziness, appetite changes, indigestion, blood pressure readings when requested, falls, sleepiness, and new confusion.
Regular reassessment helps determine whether benefit outweighs harm. For example, reducing daily verbal aggression from several prolonged episodes to an occasional brief event may represent meaningful improvement, but not if the person has become too dizzy to walk safely. A new fall, seizure, severe blood-pressure elevation, or suspected serotonin syndrome requires immediate clinical attention rather than waiting for the next routine appointment.
Frequently Asked Questions
Is Auvelity an antipsychotic?
No. Auvelity combines dextromethorphan and bupropion and is classified as a non-antipsychotic treatment. It is approved for major depressive disorder and for agitation associated with dementia due to Alzheimer’s disease in adults.
Does Auvelity treat Alzheimer’s disease itself?
No. It treats agitation associated with Alzheimer’s dementia. It has not been shown to reverse memory loss, stop neurodegeneration, or slow the underlying progression of Alzheimer’s disease.
Is Auvelity the same as Rexulti?
No. Auvelity is a non-antipsychotic combination medicine. Rexulti is the atypical antipsychotic brexpiprazole. Both have an FDA-approved role in Alzheimer’s agitation, but their mechanisms, warnings, interactions, and side effects differ.
Can Auvelity be given only when agitation occurs?
No. The prescribing information specifically states that Auvelity is not indicated as an as-needed treatment for Alzheimer’s agitation. It is taken on a scheduled regimen.
Who should not take Auvelity?
Contraindications include seizure disorder, current or past anorexia nervosa or bulimia, certain abrupt drug or alcohol withdrawal situations, and use within restricted periods around monoamine oxidase inhibitors. A clinician must also review blood pressure, other medications, and liver and kidney function.
What should caregivers do if agitation suddenly becomes worse?
Seek medical assessment for possible pain, infection, dehydration, constipation, urinary retention, medication effects, delirium, or another acute problem. Sudden agitation accompanied by fever, weakness, a fall, breathing difficulty, or reduced alertness may require urgent care.
